News

Tuesday, 23 January 2018

New spin-off Ahead Therapeutics SL to develop novel therapies for autoimmune diseases

Ahead Therapeutics SL is the result of a joint research project with a strong nano component between the Germans Trias i Pujol Research Institute (IGTP), the ICN2 and ICREA. It was created to advance the development of therapies for autoimmune diseases and pursue their application in a clinical setting. Just a few months in, the new company has already attracted 1.1 million euros in private investment.

Friday, 19 January 2018

A nanophenomenon that triggers the bone-repair process

Researchers of the ICN2 Oxide Nanophysics Group led by ICREA Prof. Gustau Catalan have resolved one of the great unknowns in bone remodelling: how the cells responsible for forming new bone tissue are called into action. Their work reveals the possible role of an electromechanical phenomenon at the nanoscale, flexoelectricity, not only in stimulating the cell response, but in precisely guiding it throughout the fracture repair process.

Friday, 19 January 2018

The ICN2 in two of the three BIST Ignite projects

The Barcelona Institute of Science and Technology has awarded three second-phase grants to collaborative projects developed jointly by BIST member institutions. The ICN2's participation in two of the three successful projects is led by ICREA Prof. Jose Antonio Garrido and ICREA Prof. Jordi Arbiol.

Thursday, 11 January 2018

Nanotechnology brings together companies and research centres from both sides of the Pyrenees

A new European-funded project starting in February 2018 will enable greater cooperation between SMEs and research centres in the Spain-France border regions. Coordinated by the Basque company BihurCrystal, the ICN2 Atomic Manipulation and Spectroscopy Group led by ICREA Research Prof. Aitor Mugarza will be contributing their expertise. Here we present the official press release.